Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。